F8 haplotype and inhibitor risk: Results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

Haemophilia

Volumn 19, Issue 1, 2013, Pages 113-118

  Schwarz, J ^a   Astermark, J ^b   Menius, E D ^a   Carrington, M ^c,d   Donfield, S M ^a   Gomperts, E D ^e   Nelson, G W ^c   Oldenburg, J ^f   Pavlova, A ^f   Shapiro, A D ^g   Winkler, C A ^c   Berntorp, E ^b  

^a RHO INC   (United States)

^b LUND UNIVERSITY   (Sweden)

^c SAIC FREDERICK INC   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

Author keywords

F8 haplotype; FVIII inhibitors; Haplotype mismatch

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; HLA A ANTIGEN;

AFRICAN AMERICAN; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETICS; HAPLOTYPE; HEMOPHILIA; HLA SYSTEM; HUMAN; MALE; MISMATCH REPAIR; PRIORITY JOURNAL;

AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FACTOR VIII; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEMOPHILIA A; HUMANS; MUTATION;

EID: 84871015816     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12004     Document Type: Article

References (23)

1. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82: 500-4.
2. Astermark J, Berntorp E, White GC, Kroner BL, MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
3. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8(Suppl. 2): 23-9.
4. Pavlova A, Delev D, Lacroix-Desmazes S et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7: 2006-15.
5. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK, MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
6. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
7. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK, MIBS Study Group. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
8. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54. (Review).
9. Howard TE, Machiah DK, Tran TT et al. African-Americans express multiple haplotypic forms of the wildtype factor VIII (FVIII) protein: a possible role for pharmacogenetics in FVIII inhibitor development? Blood 2004; 104: 113a.
10. Viel KR, Ameri A, Abshire TC et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.
11. R Development Core Team (2008). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org. Accessed January 1, 2010.
12. Sinnwell JP, Schaid DJ, Yu Z (2008). Haplo.stats: statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous. R package version 1.3.8. http://mayoresearch.mayo.edu/mayo/research/schaidlab/software.cfm. Accessed January 1, 2009.
13. Oldenburg J. Mutation profiling in haemophilia A. Thromb Haemost 2001; 85: 577-9.
14. Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5: 236-41.
15. Hansen JA, ed. Immunobiology of the Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Conference, Section A5: Sequence Based HLA Typing, Vol. I. IHWG Press, Seattle, WA, 2007.
16. White GC 2nd, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost 1997; 77: 660-7.
17. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
18. Tarantino MD, Collins PW, Hay CR et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
19. Giangrande PL, KOGENATE Bayer Study Group. Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002; 8(Suppl. 2): 19-22.
20. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-9.
21. Donders AR, Van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087-91.
22. SAS Institute, Inc. SAS 9.1.3 Help and Documentation. Cary, NC: SAS Institute, Inc, 2004.
23. Falush D, Stephens M, Pritchard J. Inference of population structure using multilocus genotype data: linked loci, and correlated allele frequencies. Genetics 2003; 164: 1567-87.